Most Down Articles

Published in last 1 year | In last 2 years| In last 3 years| All| Most Downloaded in Recent Month | Most Downloaded in Recent Year|

In last 3 years

Please wait a minute...


For Selected: Download Citations EndNote Reference Manager ProCite BibTeX RefWorks Toggle Thumbnails

Select

Electronic Journal of Liver Tumor    2023, 10 (4): 1-14.   Abstract （296）      PDF （2280KB）（260）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2023, 10 (3): 1-11.   Abstract （139）      PDF （1692KB）（249）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2023, 10 (1): 1-9.   Abstract （266）      PDF （2166KB）（236）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Global liver cancer and gallbladder cancer incidence and mortality in 2020 Shan Tianhao1, An Lan1, Xu Mengyuan1, Zeng Hongmei1,*, Cai Jianqiang2,* Electronic Journal of Liver Tumor    2022, 9 (4): 46-51.   Abstract （342）      PDF （2337KB）（190）       Knowledge map    Save Objective:According to the data of GLOBOCAN 2020, we compared the global and Chinese incidence and mortality of liver cancer and gallbladder cancer in 2020, to provide a scientific basis for cancer prevention and control. Method:According to the incidence and mortality data of liver cancer and gallbladder cancer released by the International Agency for Research on Cancer in 2020, the differences among different regions, genders and ages were compared. Result:In 2020, there were 905 677 new cases and 830 180 deaths of liver cancer globally, with age-standardized incidence and mortality rates of 9.5/100 000 and 8.7/100 000, respectively. For gallbladder cancer, the numbers of new cases and deaths were 115 949 and 84 695, respectively, with the age-standardized incidence and mortality of 1.2/100 000 and 0.84/100 000, respectively. The top five countries with highest incidence of liver cancer were Mongolia, Egypt, Laos, Cambodia and Vietnam. The top five countries with highest incidence of gallbladder cancer were Bolivia, Chile, Bangladesh, Nepal and Korea. In 2020, there were 410 038 new cases of liver cancer in China, with a standardized incidence rate of 18.2/100 000, ranking 8th among all countries. There were 391 152 new cases of death from liver cancer in China, with an age-standardized mortality rate of 17.2/100 000. For gallbladder cancer, there were 28 923 new cases of incidence in China, with an age-standardized incidence rate of 1.2/100 000, ranking 39th among all countries. There were 23 297 new cases of death from gallbladder cancer in China, with an age-standardized mortality rate of 0.97/100 000. Conclusion:The disease burden of liver cancer and gallbladder cancer is different between countries. Different prevention and control strategies should be formulated according to different populations. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2022, 9 (4): 1-11.   Abstract （61）      PDF （1377KB）（88）       Knowledge map    Save Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2023, 10 (1): 49-52.   Abstract （38）      PDF （4204KB）（85）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Analysis of incidence and mortality of liver cancer in Shanxi cancer registries, 2019 Guo Xuerong, Cao Ling, Zhang Ruifeng, Wang Xinchen, Qiao Nan, Zhang Yongzhen Electronic Journal of Liver Tumor    2023, 10 (2): 27-32.   Abstract （141）      PDF （2308KB）（82）       Knowledge map    Save Objective: To analyze the incidence and mortality of liver cancer in Shanxi cancer registries in 2019, and to provide the strategies of prevention and treatment of liver cancer. Method: According to the "Chinese Guideline for Cancer Registration" and referring to the data quality audit evaluation standards formulated by the International Agency for Research on Cancer (IARC)/International Association of Cancer Registration (IACR), a summary analysis was conducted on the incidence, death, and population data of liver cancer reported by tumor registration points in Shanxi Province that meet the quality control standards. The incidence/mortality crude rate, standardized incidence/mortality rate, and the cumulative rate of 0-74 years old were calculated by gender, area (urban and rural), and age. The age-standardized of Chinese standard population (ASR China) and world standard population (ASR world) were calculated by the Chinese standard population in 2000 and Segi's population, respectively. Result: In 2019, 644 new cases of liver cancer were recorded in Shanxi cancer registries, accounting for 5.39% of all new cancer cases. The crude incidence rate was 13.18 per 100 000, with ASR China of 8.13 per 100 000 and ASR world of 8.30 per 100 000, respectively. The cumulative incidence rate (0-74 years old) was 0.96%. Liver cancer was the 7th most common cancer in the registration areas of China in 2019. The incidence of ASR China was 2.46 times in males as that in females, and it was 0.99 times in urban areas as that in rural areas. A total of 791 cases died of liver cancer in Shanxi cancer registries, accounting for 10.00% of all cancer deaths. The crude mortality rate was 16.19 per 100 000, with ASR China of 9.90 per 100 000 and ASR world of 10.06 per 100 000. The cumulative mortality rate (0-74 years old) was 1.16%. Liver cancer was the 4th most common cause of cancer deaths in the registration areas of China in 2019. The mortality of ASR China was 1.90 times in males as that in females, and it was 0.78 times in urban areas as that in rural areas. The incidence and mortality of liver cancer both increased with age, and the incidence increased more significantly after the age of 40. The incidence and mortality in Shanxi Province reached the peak in the age group of 85 years, and the male was higher than the female. Conclusion: The incidence and mortality rates of liver cancer in Shanxi cancer registries are lower than national average, the male is higher than the female, and higher in rural areas than in urban areas. Therefore, the prevention and treatment of liver cancer should focus on males and pelple in rural areas. Early diagnosis and treatment of liver cancer should be promoted to increase the detection rate of early liver cancer and reduce the disease burden caused by liver cancer. Reference | Related Articles | Metrics

Select

Progress on protein induced by vitamin K absence or antagonist-Ⅱ in the diagnosis and therapy of hepatocellular carcinoma Wang Yaning, Sheng Jiyao, Wang Zhenxiao, Zhang Xuewen Electronic Journal of Liver Tumor    2023, 10 (1): 39-44.   Abstract （161）      PDF （2033KB）（55）       Knowledge map    Save Protein induced by vitamin K absence or antagonist-Ⅱ(PIVKA-Ⅱ) is mainly used for the complementary diagnosis of hepatocellular carcinoma, but now more and more studies have found that PIVKA-Ⅱ is valuable in combination with other serological indices for highly specific and sensitive diagnosis, pre-treatment efficacy assessment and post-treatment prognosis evaluation, and its level changes can provide a new basis for choice of surgery timing of liver transplantation and hepatectomy and for microvascular invasion. This article will review and discuss the role of PIVKA-Ⅱ in the above diagnosis and treatment, aiming to provide more comprehensive theoretical support for the function of PIVKA-Ⅱ in hepatocellular carcinoma. Reference | Related Articles | Metrics

Select

Effect of narrative nursing model based on evidence-based medicine on early ambulation and compliance of patient Pan Wenbing, Lu Yao, Li Yan, Shi Zhuolin, Liu Yudi Electronic Journal of Liver Tumor    2023, 10 (3): 89-92.   Abstract （72）      PDF （1804KB）（51）       Knowledge map    Save Objective:To explore the effect of narrative nursing model based on evidence-based medicine on early ambulation and compliance of patients with primary liver cancer after transcatheter arterial chemoembolization (TACE). Methods:From December 2019 to February 2022, 70 patients with primary liver cancer undergoing TACE in our hospital were randomly divided into the control group (n=35) and the observation group (n=35) with conventional perioperative nursing and narrative nursing model based on evidence-based medicine. The early ambulation and early recovery, compliance before and after receiving nursing, quality of life score changes and postoperative complications were compared between the two groups. Results:The observation group had shorter first time out of bed activity and longer activity duration than the control group (P<0.05). The observation group had shorter anal exhaust, general food recovery, and hospitalization time in sequence compared to the control group (P<0.05). After nursing, the compliance and QLICP-LI scores of the observation group were higher than those of the control group (P<0.05). Compared with the control group, the observation group had a lower incidence of postoperative complications (P<0.05). Conclusion:The narrative nursing model based on evidence-based medicine for patients with primary liver cancer after TACE can shorten the time of early ambulation, promote postoperative recovery, reduce the occurrence of postoperative complications, improve patient compliance, and improve the quality of life. Reference | Related Articles | Metrics

Select

Progress on the mechanism of lenvatinib resistance in hepatocellular carcinoma Zhang Lisha, Kang Mingjia, Zhao Jian Electronic Journal of Liver Tumor    2023, 10 (2): 37-40.   Abstract （211）      PDF （1635KB）（50）       Knowledge map    Save Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Lenvatinib is an inhibitor of multiple receptor tyrosine kinases, was approved in 2018 for the first-line treatment of unresectable HCC. However, the inevitable drug resistance of lenvatinib is the main reason that hindering its long-term anticancer activity, but the mechanism of drug resistance is not completely clear. In this paper, the potential mechanisms of resistance to lenvatinib in HCC were reviewed according to signal pathway and targets classification, providing reference for research on prevention or delay of lenvatinib resistance. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2023, 10 (1): 10-14.   Abstract （107）      PDF （2050KB）（50）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2022, 9 (1): 23-28.   Abstract （70）      PDF （2165KB）（50）       Knowledge map    Save Reference | Related Articles | Metrics

Select

The mechanism of histone deacetylase inhibitor vorinostat inhibiting the growth of hepatocellular carcinoma cells Gu Xinglu, Zhao Xiaohang, Sun Yulin Electronic Journal of Liver Tumor    2023, 10 (1): 15-24.   Abstract （129）      PDF （9724KB）（47）       Knowledge map    Save Objective: To investigate the mechanism of exonuclease 1 (EXO1) in hepatocellular carcinoma (HCC) and the possible mechanism of the histone deacetylase (HDAC) inhibitor vorinostat inhibiting the growth of HCC cells. Methods: HCC cell lines with knockdown or overexpression of EXO1 were constructed. And the effects of EXO1 on the proliferation, migration and invasion in HCC were investigated by cell phenotype assays. The role of EXO1 in homologous recombination (HR) repair and its effect on ionizing radiation sensitivity of cells were detected by HR reportor assay, immunofluorescence and western blots. Additionally, HCC cells were treated with vorinostat. The effect of vorinostat on EXO1 expression and the possible mechanism of inhibiting the growth of HCC cells were detected by CCK-8, flow cytometry and Western blotting. Results: High level of EXO1 promoted the proliferation, migration and invasion of HCC cells. EXO1 also promoted DNA double-strand break repair through the HR pathway and reduced cell sensitivity to ionizing radiation. In addition, elevated EXO1 levels were less sensitive to vorinostat, whereas knockdown of EXO1 increased the sensitivity of hepatocellular carcinoma cells to vorinostat. Vorinostat further inhibited the HR repair ability of HCC cells by suppressing EXO1 expression, thereby inhibiting cell growth. Conclusion: Vorinostat can inhibit HR repair ability by decreasing the expression level of EXO1, which may serve as a potential therapeutic target for HCC Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2022, 9 (4): 59-62.   Abstract （87）      PDF （4865KB）（47）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Research progress of radiotherapy for extrahepatic cholangiocarcinoma Yang Yongjing, Liu Tingting, Liu Shixin Electronic Journal of Liver Tumor    2023, 10 (3): 83-88.   Abstract （38）      PDF （1982KB）（43）       Knowledge map    Save Extrahepatic cholangiocarcinoma has a high risk of local recurrence after surgical resection, so adjuvant therapy is needed to improve relapse-free survival and overall survival, among which radiotherapy is an important treatment. This article reviews the role of adjuvant radiotherapy, neoadjuvant radiotherapy, radical radiotherapy and palliative radiotherapy in the treatment of extrabiliary cholangiocarcinoma. Some studys showed that postoperative adjuvant chemoradiotherapy could improve the disease-free survival and overall survival of patients with extrahepatic cholangiocarcinoma. The results of liver transplantation alone have been disappointing for unresectable hilar cholangiocarcinoma, and neoadjuvant chemoradiotherapy combined with liver transplantation has been explored with encouraging results in unresectable hilar cholangiocarcinoma. For unresectable extrahepatic cholangiocarcinoma, radical chemoradiotherapy prolongs survival. Stenting combined with palliative radiotherapy can improve stent patency and improve the quality of life of patients. Radiotherapy combined with effective multimodal therapy holds promise for improving the survival rate of extrahepatic cholangiocarcinoma. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2023, 10 (3): 12-26.   Abstract （58）      PDF （3747KB）（38）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2023, 10 (1): 53-56.   Abstract （81）      PDF （1659KB）（37）       Knowledge map    Save Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2023, 10 (3): 104-105.   Abstract （56）      PDF （1994KB）（33）       Knowledge map    Save Related Articles | Metrics

Select

The global status and development trends of radioembolization for liver cancer with yttrium-90: a bibliometric analysis Tang Fan, Luo Yingen, Ou Aixin, Xu Haoran, Li Xiao Electronic Journal of Liver Tumor    2023, 10 (3): 38-47.   Abstract （68）      PDF （12361KB）（30）       Knowledge map    Save Objective:To investigate the global status and development trends of radioembolization for liver cancer with yttrium-90 through bibliometric analysis. Method:All available data of the articles concerning radioembolization for liver cancer with yttrium-90, based on Web of Science database from 1991 to 2021, were analyzed with bibliometric analysis for creating visual knowledge maps of the countries, institutions, authors, journals and keywords by VOS viewer. Result:According to the search strategy and screening criteria, a total of 989 articles related to radioembolization for liver cancer with yttrium-90 were included in this study, involving 4 406 researchers from 1 055 institutions in 47 countries. The overall number of annual and cumulative publications significantly showed an upward trend, reaching a peak in 2021. United States dominated in national cooperation and number of articles. The top three institutions of total publications were Northwestern University, University of Navarra and Washington University. The top three authors of total publications and citations were Salem R, Lewandowski RJ and Mulcahy MF. Journal of Vascular and Interventional Radiology and other journals have played a vital role in promoting the development of this field. The top 10 keywords with occurrence frequency were radioembolization, hepatocellular carcinoma, yttrium-90, Y-90 microspheres, survival, cancer, liver metastases, microspheres, selective internal radiation therapy and internal radiation therapy. Conclusion:Radioembolization for liver cancer with yttrium-90 is one of the important research hotspots of liver cancer. Chinese researchers should not only pay attention to the frontier research in this field, but also actively carry out multicenter clinical research projects. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2023, 10 (2): 1-6.   Abstract （74）      PDF （5133KB）（29）       Knowledge map    Save Reference | Related Articles | Metrics